Table 1 Characteristics of patients distributed by development or not of aspergillosis
Total | Developing aspergillosis | p | ||
|---|---|---|---|---|
No | Yes | |||
n | 67 | 55 | 12 | |
No. respiratory episodes; median (IQR) | 2 (1.0–4.0) | 2 (1.0–3.0) | 3 (2.0–4.8) | 0.061 |
Age; mean ± SD | 73.1 ± 14.9 | 73.7 ± 15.4 | 70.2 ± 12.7 | 0.468 |
≥70 years | 48 (71.6) | 49 (72.7) | 8 (66.7) | 0.729 |
COPD | 47 (70.4) | 35 (63.6) | 12 (100) | 0.012 |
GOLD category | ||||
III | 17 (29.3) | 14 (30.4) | 3 (25.0) | 1.000 |
IV | 18 (31.0) | 12 (26.1) | 6 (50.0) | 0.046 |
Diabetes mellitus II | 13 (19.4) | 11 (20.0) | 2 (16.7) | 1.000 |
Congestive heart failure | 9 (13.4) | 7 (12.7) | 2 (16.7) | 0.658 |
Liver disease | 7 (10.4) | 5 (9.1) | 2 (16.7) | 0.600 |
Chronic renal insufficiency | 7 (10.4) | 7 (12.7) | 0 (0.0) | 0.336 |
Charlson index; mean ± SD | 2.4 ± 1.7 | 2.4 ± 1.8 | 2.6 ± 1.6 | 0.744 |
APACHE; mean ± SD | 12.5 ± 5.0 | 12.1 ± 5.0 | 14.4 ± 5.0 | 0.142 |
McCabe (rapidly fatal) | 11 (16.4) | 9 (16.3) | 2 (16.7) | 1.000 |
ICU admission | 5 (7.5) | 4 (7.3) | 1 (8.3) | 1.000 |
Mechanical ventilation | 6 (9.0) | 5 (9.1) | 1 (8.3) | 1.000 |
Previous steroids intake (3 months) | 24 (35.8) | 20 (36.4) | 4 (33.3) | 1.000 |
Previous antibiotics intake (30 days) | 28 (41.8) | 22 (40.0) | 6 (50.0) | 0.538 |
Previous antifungals intake (30 days) | 9 (13.4) | 7 (12.7) | 2 (16.7) | 0.658 |
Antifungals in the present episode | 7 (10.4) | 2 (3.6) | 5 (41.7) | 0.001 |